

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: AOKI et al.) Examiner: Anish Gupta
 U.S. Serial No.: 09/490,756) Art Unit: 1653
 Filed: January 24, 2000)
 For: METHOD FOR TREATING DYSTONIA)
WITH BOTULINUM TOXIN TYPE B) Irvine, California



**SUPPLEMENTARY
 INFORMATION DISCLOSURE STATEMENT**

Assistant Commissioner for Patents
 Washington, D.C. 20231

Dear Sir:

Applicant provides with regard to the above-referenced patent application one copy of each of the thirteen documents listed on the attached two-page Form PTO-1449, which may be material to the examination of this application, and in respect of which there may be a duty of disclosure under 37 C.F.R. §1.56.


While these documents may be material pursuant to 37 C.F.R. §1.56, their disclosure is not intended to constitute an admission that any such document is prior art in regard to this invention. The filing of this Statement should not be construed to mean that a search has been conducted or that no other material documents or information exists. Please do not hesitate to contact the undersigned should any questions arise regarding this Statement.

The Commissioner is hereby authorized to charge any fees associated with this communication, or credit any overpayment, to Deposit Account No. 01-0885.

Respectfully submitted,

Allergan, Inc.
 2525 Dupont Drive
 Irvine, CA 92612

Date: July 10, 2000


 Stephen Donovan
 Registration Number 33,433
 Tel: 714 246 4026
 Fax: 714 246 4249

CERTIFICATE OF MAILING UNDER 37 C.F.R. § 1.8

I hereby certify that this Supplementary Information Disclosure Statement and any additional documents set forth as being enclosed herein are being deposited with the United States Postal Service on the date shown below, with sufficient postage as first class mail in an envelope addressed to Assistant Commissioner for Patents, Washington, DC 20231.

Date: July 11, 2000

Mary Stickle
 Name of Person Mailing

Mary Stickle
 Signature of Person Mailing